Enhabit (NYSE:EHAB) Earns Market Perform Rating from Leerink Partners

Enhabit (NYSE:EHAB)‘s stock had its “market perform” rating restated by equities research analysts at Leerink Partners in a report issued on Tuesday,Benzinga reports. They presently have a $8.00 price target on the stock, down from their prior price target of $8.50. Leerink Partners’ price objective indicates a potential upside of 13.64% from the company’s previous close.

Enhabit Trading Down 1.4 %

Shares of NYSE EHAB traded down $0.10 during trading on Tuesday, reaching $7.04. The company had a trading volume of 23,093 shares, compared to its average volume of 579,649. The stock has a market cap of $353.97 million, a P/E ratio of -3.03 and a beta of 1.84. The company’s fifty day moving average price is $7.56 and its 200-day moving average price is $8.47. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.85. Enhabit has a 12 month low of $6.85 and a 12 month high of $11.74.

Enhabit (NYSE:EHAB) last announced its earnings results on Wednesday, November 6th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.01). The business had revenue of $253.60 million for the quarter, compared to the consensus estimate of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same quarter in the previous year, the company earned $0.03 EPS. As a group, research analysts expect that Enhabit will post 0.25 earnings per share for the current year.

Insider Buying and Selling at Enhabit

In related news, Director Jeffrey Bolton acquired 5,000 shares of the firm’s stock in a transaction on Thursday, August 22nd. The stock was purchased at an average cost of $8.01 per share, with a total value of $40,050.00. Following the acquisition, the director now owns 78,877 shares of the company’s stock, valued at approximately $631,804.77. This trade represents a 6.77 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.90% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Enhabit

Large investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new stake in Enhabit in the 1st quarter worth about $44,000. ProShare Advisors LLC bought a new position in Enhabit in the 1st quarter valued at $118,000. State Board of Administration of Florida Retirement System grew its stake in Enhabit by 268.2% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 52,932 shares of the company’s stock valued at $617,000 after purchasing an additional 38,555 shares during the period. Orion Portfolio Solutions LLC increased its position in shares of Enhabit by 72.5% during the 1st quarter. Orion Portfolio Solutions LLC now owns 96,833 shares of the company’s stock valued at $1,128,000 after purchasing an additional 40,684 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Enhabit by 5.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 37,950 shares of the company’s stock worth $443,000 after purchasing an additional 2,078 shares during the period.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.